Literature DB >> 18762245

Oxidative damage in brain from human mutant APP/PS-1 double knock-in mice as a function of age.

Hafiz Mohmmad Abdul1, Rukhsana Sultana, Daret K St Clair, William R Markesbery, D Allan Butterfield.   

Abstract

Oxidative stress is strongly implicated in the progressive decline of cognition associated with aging and neurodegenerative disorders. In the brain, free radical-mediated oxidative stress plays a critical role in the age-related decline of cellular function as a result of the oxidation of proteins, lipids, and nucleic acids. A number of studies indicate that an increase in protein oxidation and lipid peroxidation is associated with age-related neurodegenerative diseases and cellular dysfunction observed in aging brains. Oxidative stress is one of the important factors contributing to Alzheimer's disease (AD), one of whose major hallmarks includes brain depositions of amyloid beta-peptide (Abeta) derived from amyloid precursor protein (APP). Mutation in APP and PS-1 genes, which increases production of the highly amyloidogenic amyloid beta-peptide (Abeta42), is the major cause of familial AD. In the present study, protein oxidation and lipid peroxidation in the brain from knock-in mice expressing human mutant APP and PS-1 were compared with brain from wild type, as a function of age. The results suggest that there is an increased oxidative stress in the brain of wild-type mice as a function of age. In APP/PS-1 mouse brain, there is a basal increase (at 1 month) in oxidative stress compared to the wild type (1 month), as measured by protein oxidation and lipid peroxidation. In addition, age-related elevation of oxidative damage was observed in APP/PS-1 mice brain compared to that of wild-type mice brain. These results are discussed with reference to the importance of Abeta42-associated oxidative stress in the pathogenesis of AD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18762245      PMCID: PMC2597707          DOI: 10.1016/j.freeradbiomed.2008.08.012

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  60 in total

Review 1.  Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide.

Authors:  D A Butterfield; J Drake; C Pocernich; A Castegna
Journal:  Trends Mol Med       Date:  2001-12       Impact factor: 11.951

2.  Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A beta(1--42) and A beta(25--35).

Authors:  S Varadarajan; J Kanski; M Aksenova; C Lauderback; D A Butterfield
Journal:  J Am Chem Soc       Date:  2001-06-20       Impact factor: 15.419

Review 3.  Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress.

Authors:  D Allan Butterfield; Christopher M Lauderback
Journal:  Free Radic Biol Med       Date:  2002-06-01       Impact factor: 7.376

4.  The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42.

Authors:  C M Lauderback; J M Hackett; F F Huang; J N Keller; L I Szweda; W R Markesbery; D A Butterfield
Journal:  J Neurochem       Date:  2001-07       Impact factor: 5.372

5.  In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1-42)

Authors:  S M Yatin; S Varadarajan; C D Link; D A Butterfield
Journal:  Neurobiol Aging       Date:  1999 May-Jun       Impact factor: 4.673

Review 6.  Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment.

Authors:  B Halliwell
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

7.  Neurodegenerative changes associated with beta-amyloid deposition in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes.

Authors:  M A Kurt; D C Davies; M Kidd; K Duff; S C Rolph; K H Jennings; D R Howlett
Journal:  Exp Neurol       Date:  2001-09       Impact factor: 5.330

8.  Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1.

Authors:  Alessandra Castegna; Michael Aksenov; Marina Aksenova; Visith Thongboonkerd; Jon B Klein; William M Pierce; Rosemarie Booze; William R Markesbery; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2002-08-15       Impact factor: 7.376

9.  Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71.

Authors:  Alessandra Castegna; Michael Aksenov; Visith Thongboonkerd; Jon B Klein; William M Pierce; Rosemarie Booze; William R Markesbery; D Allan Butterfield
Journal:  J Neurochem       Date:  2002-09       Impact factor: 5.372

10.  FAD mutant PS-1 gene-targeted mice: increased A beta 42 and A beta deposition without APP overproduction.

Authors:  Dorothy G Flood; Andrew G Reaume; Karen S Dorfman; Yin Guo Lin; Diane M Lang; Stephen P Trusko; Mary J Savage; Wim G Annaert; Bart De Strooper; Robert Siman; Richard W Scott
Journal:  Neurobiol Aging       Date:  2002 May-Jun       Impact factor: 4.673

View more
  34 in total

Review 1.  Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease.

Authors:  Magali Dumont; Michael T Lin; M Flint Beal
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 2.  Neuroprotective strategies involving ROS in Alzheimer disease.

Authors:  Magali Dumont; M Flint Beal
Journal:  Free Radic Biol Med       Date:  2010-12-01       Impact factor: 7.376

3.  Proteomic analysis of brain proteins in APP/PS-1 human double mutant knock-in mice with increasing amyloid β-peptide deposition: insights into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer's disease.

Authors:  Renã A S Robinson; Gururaj Joshi; Quanzhen Huang; Rukhsana Sultana; Austin S Baker; Jian Cai; William Pierce; Daret K St Clair; William R Markesbery; D Allan Butterfield
Journal:  Proteomics       Date:  2011-09-22       Impact factor: 3.984

4.  Oxidatively generated DNA damage after Cu(II) catalysis of dopamine and related catecholamine neurotransmitters and neurotoxins: Role of reactive oxygen species.

Authors:  Wendy A Spencer; Jeyaprakash Jeyabalan; Sunita Kichambre; Ramesh C Gupta
Journal:  Free Radic Biol Med       Date:  2010-11-12       Impact factor: 7.376

Review 5.  Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies.

Authors:  Aaron M Swomley; Sarah Förster; Jierel T Keeney; Judy Triplett; Zhaoshu Zhang; Rukhsana Sultana; D Allan Butterfield
Journal:  Biochim Biophys Acta       Date:  2013-10-09

Review 6.  Redox proteomics and amyloid β-peptide: insights into Alzheimer disease.

Authors:  D Allan Butterfield; Debra Boyd-Kimball
Journal:  J Neurochem       Date:  2018-11-27       Impact factor: 5.372

7.  Alzheimer's-associated Abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal.

Authors:  Jason Pitt; William Roth; Pascale Lacor; Amos B Smith; Matthew Blankenship; Pauline Velasco; Fernanda De Felice; Paul Breslin; William L Klein
Journal:  Toxicol Appl Pharmacol       Date:  2009-07-23       Impact factor: 4.219

8.  Fourier transform infrared imaging showing reduced unsaturated lipid content in the hippocampus of a mouse model of Alzheimer's disease.

Authors:  Andreana C Leskovjan; Ariane Kretlow; Lisa M Miller
Journal:  Anal Chem       Date:  2010-04-01       Impact factor: 6.986

Review 9.  Proteomic approaches to quantify cysteine reversible modifications in aging and neurodegenerative diseases.

Authors:  Liqing Gu; Renã A S Robinson
Journal:  Proteomics Clin Appl       Date:  2016-11-11       Impact factor: 3.494

10.  Age-related loss of phospholipid asymmetry in APP(NLh)/APP(NLh) x PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice: relevance to Alzheimer disease.

Authors:  Miranda L Bader Lange; Daret St Clair; William R Markesbery; Christa M Studzinski; M Paul Murphy; D Allan Butterfield
Journal:  Neurobiol Dis       Date:  2010-01-18       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.